- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.07. | Ultomiris fail mars AZ's strong Q2 results | ||
| 24.07. | Ipsen' Bylvay fluffs its lines in biliary atresia trial | ||
| 24.07. | Sanofi gives up on amlitelimab in atopic dermatitis | ||
| 24.07. | Re-rostered FDA committee backs peptide compounding | ||
| 24.07. | J&J's multiple myeloma duo aces phase 3 trial | ||
| 23.07. | Dexcom is first to join FDA/CMS health tech pilot | ||
| 23.07. | Lilly plans Q1 2027 filing for obesity triple retatrutide | ||
| 23.07. | EU clears AZ's SERD camizestrant, as FDA review drags on | ||
| 23.07. | Nuvalent buy delivers new cancer approval for GSK | ||
| 23.07. | As patents expire, fampridine is cleared for NHS use in MS | ||
| 23.07. | Takeda gets first OK for orexin narcolepsy drug, in China | ||
| 22.07. | Repligen builds in cell therapy with $1.5bn BioLife Solutions takeover | ||
| 22.07. | Kaken details the data behind its PI3K inhibitor filing | ||
| 22.07. | Precision Neuro breaks new ground in BCI technology | ||
| 22.07. | Gilead, MSD share data on once-weekly oral HIV treatment | ||
| 22.07. | Trump sets course for 100%, then 200%, tariffs on generics | ||
| 21.07. | Novo sues Lilly over 'misleading' GLP-1 ad campaigning | ||
| 21.07. | Agios shares slide as it abandons sickle cell candidate | ||
| 21.07. | Jasper and Kira merge to build immune-focused biotech | ||
| 21.07. | Novartis weathers Entresto slump with return to growth | ||
| 21.07. | New UK PM shuts down science and tech department | ||
| 20.07. | Lundbeck preps for key bexicaserin data around year-end | ||
| 20.07. | BMS, NVIDIA to build 'most powerful' AI factory | ||
| 20.07. | Samsung Biologics agrees $1.81bn takeover of PolyPeptide | ||
| 20.07. | BlossomHill, VogenX and Latigo reveal IPO plans |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.